

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3334409

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
INNOVIMMUNE BIOTHERAPEUTICS, INC.	04/30/2015
RECEIVING PARTY DATA	
Name:	INNOV88 LLC
Street Address:	760 PARKSIDE AVENUE
Internal Address:	SUITE 208
City:	BROOKLYN
State/Country:	NEW YORK
Postal Code:	11226
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13184058
CORRESPONDENCE DATA	
Fax Number:	(973)596-0545
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	9735964500
Email:	IPDocket@gibbonslaw.com
Correspondent Name:	SAMUEL H. MEGERDITCHIAN
Address Line 1:	ONE GATEWAY CENTER
Address Line 4:	NEWARK, NEW JERSEY 07102-5310
ATTORNEY DOCKET NUMBER:	112631-88762 (INOV-001)
NAME OF SUBMITTER:	SAMUEL H. MEGERDITCHIAN
SIGNATURE:	/SAMUEL H. MEGERDITCHIAN/
DATE SIGNED:	04/30/2015
Total Attachments: 2	
source=112631-88762 - Assignment from Innovimmune to INOV88 LLC#page1.tif	
source=112631-88762 - Assignment from Innovimmune to INOV88 LLC#page2.tif	

ASSIGNMENT

WHEREAS,

INNOVIMMUNE BIOTHERAPEUTICS, INC.,

a corporation, having its principal place of business at 760 Parkside Avenue, Suite 208, Brooklyn, New York, 11226,

(Assignor) have invented certain new and useful improvements which are described and claimed in United States Patent Application No. 13/184,058, filed July 15, 2011, entitled

MIF INHIBITORS AND THEIR USES

which claims priority from two U.S. Provisional Application Nos.: 61/365,070, filed July 16, 2010, and 61/381,662, filed September 10, 2010.

WHEREAS,

INNOV88 LLC,

a corporation having its principal place of business at 760 Parkside Avenue, Suite 208, Brooklyn, New York, 11226, (Assignee), is desirous of acquiring the entire interest in and to said invention, said applications and all patents to be obtained therefrom.

NOW, THEREFORE, for and in consideration of valuable consideration, the receipt and sufficiency whereof are hereby acknowledged, we have sold, assigned, and set over, and by these presents do hereby sell, assign and set over unto the said

INNOV88 LLC,

(Assignee), and said Assignee's legal representatives, successors, the entire right, title and interest, for the whole world, in and to said invention and said applications, as well as any subsequent application which claims priority based upon the filing date of any of said applications identified and the patents, both domestic and foreign, that may or shall result therefrom including the right to claim in respect of any subsequent United States and foreign patent applications and patents, the priority date of any of said applications under any United States statute and international convention or treaty; and we do hereby authorize and request the issuance of said patents, domestic and foreign, conformably to the terms of this Agreement.

UPON SAID CONSIDERATION, we do hereby covenant and agree with said Assignee that we will not execute any writing or do any act whatsoever conflicting with these presents, and that will at any time upon request, without further or additional consideration, but at the expense of the said Assignee, execute such additional

assignments and other writings and so such additional acts as said Assignee may deem necessary or desirable to perfect the Assignee's enjoyment of this grant, and render all necessary assistance in making application for and obtaining provisional, original, continuation, continuation-in-part, divisional, reissued, re-examined or extended patent of the United States or of any and all foreign countries on said invention, and in enforcing any rights or chooses in action accruing as a result of such applications or patents, including but not limited to, giving testimony in any proceedings or transactions involving such applications or patents, and executing preliminary statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind and inure to the benefit of the assigns and legal representatives of all parties hereto.


IN WITNESS WHEREOF, we have hereunto set our hands and affixed our seals this day of April 30, 2015.

INNOVIMMUNE BIOTHERAPEUTICS, INC.

April 30, 2015

Date

By:



Anderson Gaweco

Title: President

#2208102 v1
112631-88762